Atlanta, Georgia, April 26, 2019 — Biomatics Capital, a leading Seattle based life science venture capital firm, announced the closing of an investment in Guide Therapeutics, Inc. (GuideRx), a company enabling the next generation of gene therapies by developing delivery solutions for drugs to reach a wide variety of cells beyond the liver. Biomatics joins GreatPoint Ventures as core investors in GuideRx. GuideRx was organized around the work of Professor James E. Dahlman, formerly of the labs of pioneers in gene therapy including Robert Langer of MIT and Feng Zhang of the Broad Institute. Dr. Dahlman was recently recognized by MIT Technology Review as one of the Top 35 Scientists under 35 for this work. Guide has the ability to rapidly identify LNPs that show functional response in vivo with high affinity for non-liver cell types and low affinity for non-target tissues. GuideRx’s unique patented platform technology is expected to greatly extend the potential for treating genetic disease using LNPs.
Tom Saylor, CEO of GuideRx said, “Biomatics Capital provides GuideRx with not only financial support but strong experience in life science strategies. With non-liver delivery representing an important bottleneck for the wider application of LNPs as drugs, GuideRx is well-positioned to lead the field. GuideRx, in partnership with Biomatics and GreatPoint is building the platform for the next generation of safe and effective gene medicines.”
Boris Nikolic, Mananging Director at Biomatics Capital stated, “Biomatics is excited about the potential of GuideRx and its platform for advancing gene therapy as gene therapy emerges to the forefront of therapeutic opportunity. GuideRx holds strong potential to become one of the top players in the rapidly emerging field of gene therapy.”